FDA Adds Warnings to Celexa’s Label


Following up on last August’s warning that high doses of Celexa can cause potentially fatal heart rhythm abnormalities, the FDA has added clarification to the drug’s label that it should not be used at doses greater than 40 milligrams, and is not recommended for patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent heart attack, or uncompensated heart failure. The maximum recommended dose is 20 mg per day for patients with liver impairment, who are older than 60, or patients who take Tagamet of are otherwise impaired metabolizers of CYP 2C19.

Article → 


Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.


Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.

Previous articleJ&J Tries, Fails to Squeeze Whistle Blower in Texas Risperdal Case
Next articleAuditory Hallucinations – Expectation, Interpretation, and Emotion
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected].